X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3224) 3224
Book Review (1239) 1239
Publication (293) 293
Newspaper Article (223) 223
Book / eBook (85) 85
Newsletter (76) 76
Book Chapter (54) 54
Magazine Article (48) 48
Conference Proceeding (32) 32
Trade Publication Article (31) 31
Dissertation (18) 18
Transcript (18) 18
Data Set (2) 2
Reference (2) 2
Report (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2358) 2358
humans (2227) 2227
hiv (1880) 1880
hiv infections - drug therapy (1540) 1540
human immunodeficiency virus--hiv (1234) 1234
drug therapy (914) 914
hiv infection (901) 901
antiviral agents (881) 881
antiretroviral therapy (867) 867
antiretroviral drugs (864) 864
infectious diseases (861) 861
female (845) 845
male (841) 841
pharmacology & pharmacy (798) 798
adult (704) 704
anti-hiv agents - therapeutic use (681) 681
highly active antiretroviral therapy (644) 644
health aspects (634) 634
aids (601) 601
middle aged (577) 577
protease inhibitors (499) 499
acquired immune deficiency syndrome--aids (477) 477
hiv-1 - drug effects (456) 456
human-immunodeficiency-virus (448) 448
anti-hiv agents - adverse effects (442) 442
hiv infections - virology (437) 437
research (406) 406
immunology (404) 404
hiv patients (398) 398
care and treatment (388) 388
infection (376) 376
anti-hiv agents - administration & dosage (363) 363
therapy (357) 357
raltegravir (346) 346
analysis (344) 344
virology (333) 333
treatment outcome (331) 331
infections (327) 327
drug interactions (319) 319
viral load (315) 315
hiv infections - complications (314) 314
pharmacokinetics (314) 314
hiv-1 (313) 313
drug therapy, combination (309) 309
risk factors (308) 308
human immunodeficiency virus (304) 304
animals (301) 301
drug resistance (290) 290
dosage and administration (288) 288
double-blind (285) 285
antiretroviral agents (283) 283
virus diseases (281) 281
clinical trials (276) 276
patients (275) 275
aids/hiv (274) 274
medicine & public health (272) 272
tenofovir (262) 262
active antiretroviral therapy (251) 251
microbiology (249) 249
safety (249) 249
anti-hiv agents - pharmacology (243) 243
drugs (234) 234
efavirenz (234) 234
raltegravir potassium (231) 231
medical research (226) 226
proteases (224) 224
review (224) 224
medicine (218) 218
internal medicine (217) 217
hiv integrase inhibitors - therapeutic use (215) 215
article (213) 213
usage (208) 208
young adult (206) 206
cd4 lymphocyte count (205) 205
antiretroviral therapy, highly active (204) 204
ritonavir (204) 204
viruses (204) 204
prevention (201) 201
drug resistance, viral (200) 200
acquired immune deficiency syndrome (199) 199
anti-retroviral agents - therapeutic use (199) 199
hiv-infected patients (199) 199
efficacy (198) 198
infected patients (197) 197
pharmacology (196) 196
hiv integrase inhibitors - adverse effects (192) 192
mortality (190) 190
integrase (188) 188
hiv infections - epidemiology (185) 185
hiv infections - immunology (183) 183
adolescent (181) 181
emtricitabine (179) 179
adults (176) 176
studies (175) 175
complications and side effects (174) 174
immunodeficiency-virus type-1 (174) 174
research article (174) 174
toxicity (173) 173
aged (168) 168
medicine, general & internal (168) 168
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (69) 69
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
UofT at Scarborough - Stacks (4) 4
Credit Valley Hospital - Stacks (3) 3
UofT at Mississauga - Stacks (3) 3
Humber River Regional Hospital - Church Stacks (2) 2
Humber River Regional Hospital - Finch Stacks (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
Online Resources - Online (2) 2
Providence Healthcare - Reference (2) 2
Robarts - Stacks (2) 2
St. Michael's Hospital - Stacks (2) 2
Toronto East General Hospital - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Credit Valley Hospital - May be requested in 6-10 wks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
University College (Laidlaw) - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3703) 3703
Spanish (31) 31
German (15) 15
French (5) 5
Turkish (3) 3
Japanese (2) 2
Russian (2) 2
Chinese (1) 1
Dutch (1) 1
Korean (1) 1
Norwegian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9893, pp. 700 - 708
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9569, pp. 1261 - 1269
Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANTIRETROVIRAL DRUGS | THERAPY | HIV-1-INFECTED INDIVIDUALS | INFECTION | DRUG-RESISTANCE | PREVALENCE | ENFUVIRTIDE | HIV-1 | Drug Resistance, Multiple | Humans | Middle Aged | Male | HIV Integrase Inhibitors - administration & dosage | Viral Load | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | Atazanavir Sulfate | Adult | Female | Raltegravir Potassium | Organic Chemicals - administration & dosage | Pyridines - therapeutic use | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Logistic Models | Treatment Outcome | Pyrrolidinones | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Pyridines - pharmacology | Oligopeptides - pharmacology | Viral drug resistance | Care and treatment | Dosage and administration | Drug therapy | HIV infection | Raltegravir | Design | Studies | Antiretroviral drugs | Plasma | Inhibitor drugs | Protease inhibitors | Conferences | Human immunodeficiency virus--HIV | Mortality | Gene expression | Drug resistance | Patients | RNA-directed DNA polymerase | Laboratories | Toxicity | Viruses | Genomes | Randomization | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Safety | Drug dosages | Integrase | Phenotypes | Effectiveness | Proteinase inhibitors | Ribonucleic acid--RNA | Antiretroviral therapy | CD4 antigen | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Nucleosides | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 01/2013, Volume 62, Issue 1, pp. 21 - 27
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 12/2006, Volume 43, Issue 5, pp. 509 - 515
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2013, Volume 56, Issue 2, pp. 300 - 306
Journal Article
Journal of Infectious Diseases, ISSN 0022-1899, 10/2015, Volume 212, Issue 8, pp. 1241 - 1249
Background. Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to... 
human immunodeficiency virus | bone mineral density | protease inhibitor | inflammation | integrase inhibitor | INTIMA-MEDIA THICKNESS | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | TURNOVER | EMTRICITABINE | MICROBIOLOGY | OSTEOPROTEGERIN | IMMUNOLOGY | HIV-INFECTED ADULTS | PROTEASE INHIBITORS | THERAPY | RECEPTOR ACTIVATOR | Raltegravir Potassium - adverse effects | Humans | Middle Aged | Raltegravir Potassium - therapeutic use | Male | Atazanavir Sulfate - adverse effects | HIV - drug effects | Viral Load | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Tenofovir - therapeutic use | Anti-HIV Agents - adverse effects | HIV Protease Inhibitors - therapeutic use | Atazanavir Sulfate - therapeutic use | Bone Density - drug effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Darunavir - adverse effects | HIV Infections - physiopathology | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Analysis | Bones | Dosage and administration | Inflammation | HIV infection | Density | Risk factors | Index Medicus | Abridged Index Medicus | Major and Brief Reports
Journal Article
HIV Medicine, ISSN 1464-2662, 01/2017, Volume 18, Issue 1, pp. 56 - 63
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 355 - 365
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 02/2017, Volume 75, Issue 1, pp. 61 - 66
Objectiveto evaluate antiviral activity, safety, and pharmacokinetics of short-term monotherapy with bictegravir (bic), a novel, potent hiv integrase... 
Integrase strand transfer inhibitors | GS-9883 | Integrase inhibitors | Pharmacokinetics | Antiretroviral therapy | Bictegravir | ABACAVIR | bictegravir | integrase inhibitors |